Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme/Biomatrix

This article was originally published in The Gray Sheet

Executive Summary

Planned merger of Genzyme Tissue Repair, Genzyme Surgical Products and Biomatrix gains Federal Trade Commission anti-trust clearance, the companies announce June 26. Shareholder meetings are planned for the third quarter to finalize the deal. Initially anticipated to close in June, the merger has been delayed in order to respond to requests from the Securities and Exchange Commission regarding joint proxy statement
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel